Trial Profile
An Open Label Biomarker Pilot Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase 0
Latest Information Update: 08 Feb 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Biomarker; Therapeutic Use
- Acronyms D-BIOMARK
- 09 Dec 2023 Results(n=58) of subgroup analysis presented at the 46th Annual San Antonio Breast Cancer Symposium.
- 24 Oct 2023 Primary endpoint has not been met. (Antiproliferative and/or pro-apoptotic activity of denosumab) ,according to Results presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results presented at the 48th European Society for Medical Oncology Congress